Clinical Trial

Boosting Osimertinib Blood Brain Barrier Penetration

Study acronym: OSIBBBOOST
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this proof-of-concept clinical study is to determine the effect of combining osimertinib with febuxostat on cerebrospinal fluid concentrations of osimertinib in patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). The main question it aims to answer is: what is the effect of combining osimertinib with the ABCG2 inhibitor febuxostat on cerebrospinal fluid to unbound plasma osimertinib concentration ratio in patients with EGFR mutated NSCLC without central nervous system (CNS) metastases and without the ABCG2 34G\>A single nucleotide polymorphism (SNP)?
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-06
Trial Details
NCT Number NCT07485452
Lead Sponsor Maastricht University Medical Center
Collaborators: AstraZeneca, The Netherlands Cancer Institute
Conditions Non-Small Cell Lung Cancer
Enrollment 7 participants
Start Date 2026-06
Primary Completion 2027-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-05